Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreak on our timeline.

IMV has initiated plans to progress the clinical development of a Covid-19 vaccine candidate, to determine the clinical safety and immunogenicity.

Based on the company’s DPX delivery technology, the vaccine candidate DPX-COVID-19 comprises peptides that target epitopes from the novel coronavirus strain.

The peptide-based approach, along with the DPX platform, speeds up the development and production of a vaccine.

IMV plans to advance its vaccine candidate into Phase I clinical trial.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

IMV CEO Frederic Ors said: “Across our many clinical studies, we have observed DPX technology to elicit a robust immune response with a sustained effect, including in sensitive populations.

“We believe this technology offers a meaningful solution as a potential vaccine, especially in older adults and those with pre-existing conditions who are most at risk to this virus and generally more difficult to vaccinate effectively.”

The company’s Covid-19 vaccine candidate is being designed based on third-party immunological SARS-CoV studies and SARS-CoV-2 sequencing data.